• Adjusted gross profit up 22%–driven by organic growth ,a full year’s contribution from link healthcare (‘link’) and     currency benefits
      • Adjusted EPS up 25% to 41.8p (2016:33.4p)
      • Reported EPS of 3.3p (2016:11.9p)
      • Strong cash flow performance with cash generated from operations of £54.7m (2016: £49.4m)
      • Net debt substantially decreased by £33.1m to £35.0m (2016: £68.1m)
      • Full year dividend increased 25% to5.0p (2016:4.0p)
      • Strong growth across all operations
      • Outstanding performance in Africa and Asia pacific
      • Dexrazoxane portfolio revitalisation significantly enhanced by EC approval to update product information for           Cardioxane, and launch of Totect in US